February 06, 2014 11:52am EST
Download as PDF
MIAMI--(BUSINESS WIRE)--
OPKO Health, Inc. (NYSE:OPK) is pleased to announce the appointment of
Greg Stanley as Vice President of Sales and Marketing for its global
diagnostics business unit.
Mr. Stanley brings to OPKO extensive experience and expertise in the
market development and commercial operations of diagnostic products and
services. Prior to joining OPKO, Mr. Stanley served as chief commercial
officer of Oncimmune USA, LLC where he led the commercial strategy and
market development for the company’s oncology platform in early cancer
detection. Most notable was the successful launch and market growth of
EarlyCDT®-Lung, the first commercially available blood test to aid in
the early detection of lung cancer. Prior to this, Mr. Stanley served
over 5 years as director of marketing and then national director of
corporate accounts, for Roche Diagnostics where he led the successful
market introduction of numerous diagnostic products in point of care,
immunodiagnostics, hematology, clinical chemistry, blood gas, urinalysis
and blood glucose. Mr. Stanley had increasing scope of responsibility in
sales, marketing and management roles at Abbott Diagnostics, Chiron
Corporation, and Radiometer prior to his time at Roche. He has been at
the executive leadership level for over 15 years and during his tenure
served on the board of directors for Radiometer and Oncimmune. Mr.
Stanley received his B.S. degree, Business Administration, from the
University of Missouri-St. Louis.
“We are excited to have Greg joining the OPKO Diagnostics team here in
Miami,” said David Okrongly, President of OPKO Diagnostics. “His
experience at launching and gaining reimbursement for novel cancer
diagnostic tests combined with his broad background in IVD sales and
marketing is the perfect combination for the commercial leadership role
in the OPKO Diagnostics business unit.”
“We are fortunate to have Greg join the OPKO Diagnostics team where his
commercial expertise will have a significant impact as we prepare for
the launch of the 4Kscore™ prostate cancer diagnostic test and the
Claros®1 in-office immunodiagnostic analyzer,” said Phillip Frost, M.D.,
OPKO's Chairman and Chief Executive Officer.
ABOUT OPKO HEALTH, INC.
OPKO is a multinational biopharmaceutical and diagnostics company that
seeks to establish industry-leading positions in large, rapidly growing
markets by leveraging its discovery, development and commercialization
expertise and novel and proprietary technologies. For more information,
visit http://www.opko.com .
This press release includes forward looking statements, within the
meaning of the Private Securities Litigation Reform Act of 1995, which
are subject to risk and uncertainties that could cause actual results to
differ materially from those anticipated. Such statements may relate to
our plans, objectives and expected financial and operating results,
including statements relating to our products and product development
efforts, whether we launch or successfully commercialize the 4Kscore™
prostate cancer test and the Claros®1 in-office immunodiagnostic
analyzer, the expected benefits of these and other products in
development, as well as other non-historical statements about our
expectations, beliefs or intentions regarding business, technologies and
products, financial condition, strategies or prospects and other similar
statements. The words "may," "could," "would," "will," "believe,"
"anticipate," "estimate," "expect," "intend," "plan," and similar
expressions or variations thereof are intended to identify
forward-looking statements. Investors are cautioned that any such
forward-looking statements are not guarantees of future performance and
involve risks and uncertainties, many of which are beyond our ability to
control. Many factors could cause actual activities or results to differ
materially from the activities and results anticipated in
forward-looking statements. These factors include those described in our
filings with the Securities and Exchange Commission, as well as the
risks inherent in funding, developing and obtaining regulatory approvals
of new, commercially-viable and competitive products and treatments,
that earlier clinical results of effectiveness and safety may not be
reproducible or indicative of future results, that compounds or
diagnostic products under development may fail, may not achieve the
expected results or effectiveness and may not generate data that would
support the approval or marketing of products for the indications being
studied or for other indications, that products under development by
others, may prove to be as or more effective than our products for the
indications being studied. In addition, forward-looking statements may
also be adversely affected by general market factors, competitive
product development, product availability, federal and state regulations
and legislation, the regulatory process for new products and
indications, manufacturing issues that may arise, patent positions and
litigation, among other factors. The forward-looking statements
contained in this press release speak only as of the date the statements
were made, and we do not undertake any obligation to update
forward-looking statements. We intend that all forward-looking
statements be subject to the safe-harbor provisions of the PSLRA.
OPKO Health, Inc.
Steven D. Rubin or Juan F. Rodriguez, 305-575-4100
Source: OPKO Health, Inc.
Released February 6, 2014
email Email Alerts
location_city Company Profile
contact_page Contacts
rss_feed RSS News Feed
account_tree Sitemap
Apply on OPKO Health (Ireland)’s careers page